Volume | 112,151 |
|
|||||
News | - | ||||||
Day High | 2.379 | Low High |
|||||
Day Low | 2.175 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
BeyondSpring Inc | BYSI | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.18 | 2.175 | 2.379 | 2.29 | 2.11 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
503 | 112,151 | $ 2.25 | $ 252,551 | - | 0.6534 - 4.00 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:00:00 | 1,018 | $ 2.29 | USD |
BeyondSpring Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
87.18M | 38.92M | - | 1.35M | -33.28M | -0.86 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
BeyondSpring News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BYSI Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.8937 | 2.379 | 1.77 | 1.90 | 67,929 | 0.3963 | 20.93% |
1 Month | 3.53 | 3.75 | 1.76 | 2.73 | 110,635 | -1.24 | -35.13% |
3 Months | 0.9679 | 4.00 | 0.95 | 2.77 | 236,263 | 1.32 | 136.59% |
6 Months | 1.02 | 4.00 | 0.7777 | 2.43 | 135,117 | 1.27 | 124.51% |
1 Year | 1.05 | 4.00 | 0.6534 | 1.99 | 98,836 | 1.24 | 118.10% |
3 Years | 10.05 | 33.00 | 0.542 | 13.34 | 671,923 | -7.76 | -77.21% |
5 Years | 15.10 | 33.00 | 0.542 | 13.31 | 457,609 | -12.81 | -84.83% |
BeyondSpring Description
BeyondSpring Inc is engaged in clinical stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. The Company has created Plinabulin which is marine derived small-molecule with a number of distinct biological activities that may provide multiple therapeutic opportunities. Plinabulin has increased the survival of neutrophils, a type of white blood cell important in the prevention of bacterial infections. The Company has a scalable business model integrating clinical resources in the United States and China. |